T. Rowe Price Associates
KNTE

T. Rowe Price Associates’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

T. Rowe Price Associates’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-445,477
Closed -$10.4M – 3002
2021
Q2 		$10.4M Sell
445,477
-203,305
-31% -$5.17M ﹤0.01% 1413
2021
Q1 		$20.2M Sell
648,782
-624
-0.1% -$21.7K ﹤0.01% 1274
2020
Q4 		$25.8M Buy
+649,406
New +$26.1M ﹤0.01% 1156

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

T. Rowe Price Associates's KNTE Position: Q3 2021 in Review

T. Rowe Price Associates sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q3 2021, closing a stake of 445,477 shares — an estimated $10.4M sold.

T. Rowe Price Associates first reported a position in KNTE in Q4 2020 and held it in 3 quarters. The position peaked at $25.8M in Q4 2020. 73 funds tracked by Wall St. Rank hold KNTE as of Q3 2021.

  • T. Rowe Price Associates reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 445,477 Kinnate Biopharma Inc. Common Stock shares in Q3 2021, an estimated $10.4M.
  • T. Rowe Price Associates first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • T. Rowe Price Associates's Kinnate Biopharma Inc. Common Stock position peaked at $25.8M in Q4 2020.
  • 73 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q3 2021.

Based on T. Rowe Price Associates's 13F filing for Q3 2021, filed 15 Nov 2021.